SMAD2 and cardiac hypertrophy: Additionally, a reduction was also observed for the HH-EVs (ADSC) + Smad2/3 siRNA group, suggesting the capacity of this therapeutic approach to target the molecular mechanisms responsible for the onset of cardiac hypertrophy in atherosclerosis (Figure 7(B.1,B.2)).